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INTRODUCTION 
Concern over the health hazard inherent in the potent toxins pro­
duced by various strains of Clostridium botulinum has spurred a great 
deal of interest in the elucidation of procedures for detecting the 
presence of these toxins in foods, for quantitating the toxins, and for 
determining the mechanism(s) of toxin action. Unfortunately, it has not 
been possible to detect and quantitate the toxin in carrier materials 
strictly by ^  vitro analytical techniques. This procedure is accom­
plished, at the present time, on the basis of vivo assays using the 
reaction of mice or guinea pigs injected with dilutions of the suspect 
material. While biological assays are usually considered to be the ul­
timate in sensitivity, the reproducibility of results and the relatively 
slow reaction rates are serious limitations when a person's life may 
depend upon the results of the assay. For these reasons, it is of ex­
treme importance that either a revision be made of the biological assay 
technique which is now used for these toxins, or a new assay system be 
developed. 
This study was undertaken in order that a rapid, sensitive, and 
reproducible assay method might be devised for the detection and quanti­
tation of the A serotype of botulinal toxin. The completed assay is an 
in vitro method based on the inhibition of acetylcholinesterase activity 
on the chromogenic substrate, indophenyl acetate, by type A botulinal 
toxin. 
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LITERATURE REVIEW 
The first report in the literature pertaining to the toxic products 
of bacteria, in this case.to those of the diphtheria bacillus, was that 
of Rous and Yersin (1888, p. 645), who stated: "Certain bacterial species 
produce/contain antigenic poisonous substances of high molecular weight 
giving rise to more or less characteristic lesions or symptoms, including 
death, when injected into susceptible animals." Indeed, this generaliza­
tion could as well have been made regarding those strains of Clostridium 
botulinum which produce an extremely toxic protein called botulinum toxin. 
Van Ermengem (1897) first recognized and described botulism as a disease. 
He also separated the botulism syndrome from those of other types of food 
poisoning, identified the disease bacteriologically, and proved that it 
resulted from ingestion of the bacterial toxin produced by the obligately 
anaerobic bacillus which he named Bacillus botulinum, synonymous with 
the modern name, Clostridium botulinum. 
Six strains of Ç. botulinum. A, B, C, D, E, and P, can produce six 
toxins and each toxin bears the same identifying letter as the strain 
which produces it. According to Lamanna (1959), one strain of the organism 
produces only one serotype of toxin; fortunately, mutation of strains to 
produce other serotypes is unknown. Van Heyningen (1950) describes these 
toxins as typical of those produced by Gram-positive bacteria. Prévôt 
(1966) noted that the six strains are closely related, but differ from 
each other in the antigenic structure of their toxin and in some differ­
ences in their physiology. The antigenic nature of the toxins determines 
the host affected, i.e., types A, B, E, and F affect man, types C and D 
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do not. The physiological differences among these strains are mirrored 
in the difference in heat resistance of the spores (Foster et al., 1965). 
Characterization of these straias has been based most recently on a 
technique devised by Walker and Batty (1964) in which antitoxin labelled 
with fluorescein isothiocyanate is used to divide the six serotypes into 
three groups; types A, B, F; types C, D; and type E. The toxin is 
characterized further by using protection tests. Laboratory animals are 
injected with dilutions of the toxin from various strains and with pro­
tective doses of known serotypes of antitoxin. On the basis of the pro­
tection pattern, the serotype of the toxin can be determined 
Boroff (1955) observed that young cultures of these strains, growing 
and metabolizing maximally, did not produce maximum amounts of toxin. 
Instead, the toxin concentration was highest after autolysis of most of 
the organisms. The addition of 'spent' culture medium to a young culture 
promoted autolysis. On the basis of these results, Boroff suggested that 
a lytic enzyme is involved in the release of toxin from the cells. How­
ever, no conclusive data are yet available concerning this possibility, 
even though the 'autolysis factor' was shown by Boroff to be heat sensi­
tive . 
In a study by Bonventre and Kempe (1960), it was hypothesized that 
proteolytic enzymes from the autolyzed organisms act upon 'protoxin', 
an extremely large molecule which is present within the intact cell. The 
action of the enzymes, then, is to increase toxicity by the fragmentation 
of the 'protoxin'. This hypothesis also had merit in view of the evi­
dence presented earlier by Duff et al. (1956b) and Sakaguchi and 
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Sakaguchi (1959) showing that type E toxin could be activated by trypsin. 
Later, Gerwing et al. (1961) postulated that cleavage of specific amino 
acid bonds by tryptic deamination permitted 'unfolding' as well- as frag­
mentation of the toxin molecule, thereby exposing more toxic sites. This 
work was substantiated by Wagman (1962). Evidence was later presented, 
however, that fragmentation into small molecules was not likely to be 
prerequisite to an activation process (Sakaguchi et al., 1964). The 
problem of how activation of toxin is accomplished still is not resolved. 
-6 
According to Lamanna (1959), as'little as 3.5 x 10 mg of type A 
toxin can be lethal to an adult human. Because such minute quantities 
of toxin are required for poisoning, it is important to gain information 
on the structure and configuration of the molecule so as to explain the 
extreme toxicity. To determine the molecular characteristics of the 
toxins, workers have developed methods designed for obtaining high titer 
crystalline preparations. Lamanna et al. (1946), working with the 
type A strain of C. botulinum, described a technique involving the use 
of chloroform as a step in the extraction procedure. Duff et al. (1957) 
simplified the procedure greatly by using alcohol precipitation tech­
niques. Isolation of type B toxin has been described by Lamanna and 
Glassman (1947), and by Gerwing et al. (1966), and isolation of type E 
toxin has been described by Gordon et al. (1957). Type F toxin has not 
yet been purified. Extraction and purification procedures for types A, 
B, C, D, and E toxin are discussed quite comprehensively in a recent 
review by Lewis and Cassel, Jr. (1964). 
As to the mode of action of botulinal toxins, Torda and Wolff (1946) 
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state that the effect of the toxin is curare-like, decreasing the ability 
of muscle to respond to direct stimulation. Heckly et al. (1960) showed 
that' the principle site of systemic absorption is the small intestine. 
Indeed, medical dogma states that botulism occurs when botulinal toxin 
is absorbed from the gastrointestinal tract, circulates in the blood­
stream, and is delivered to the site of action, which is, apparently, 
the acetylcholine release mechanism in the peripheral nervous system. 
However, Petty (1965) mentioned other possible ways in •v^ ich the disease 
could result. For instance, if the organism could become established in 
the • ' Jstinal tract, the toxin produced would be absorbed directly into 
the jd and lead to intoxication. There also exists the possibility 
that botulism could result from toxin produced by organisms lodged in 
tissues of the body by accidental puncture wounds. It is, however, widely 
accepted in the medical field that the site of action is on the presynap­
tic junction of the cholinergic synapses (Lewis and Cassel, Jr., 1964). 
In fact, unequivocal evidence of nerve-induced acetylcholine release from 
poisoned nerve muscle preparations was presented twenty years ago by 
Burgen et al. (1948). 
The outbreaks of botulism in the period 1899-1949, as discussed by 
Osheroff et al. (1964), relate to a variety of home-processed foods. 
Death of victims is usually ascribed to suffocation due to paralysis of 
respiratory muscles. Specific antitoxins to each serotype of toxin, 
commercially produced in horses through injection of toxoid preparations, 
are available for specific treatment of intoxicated individuals. Bowmer 
(1963) gives the details of preparation and assay of the international 
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standards for types A, B, C, D, and E antitoxins. 
In order to treat a suspected case of botulism with specific anti­
toxin, it is first necessary to determine both the type and quantity of 
toxin present in the suspect material. A very important consideration 
to be made in this context is the effect of the material used as diluent 
on the toxin and on the toxin-containing carrier. Type A toxin was 
shown by Buehler et al, (1947) to be a protein possessing the properties 
of a globulin, and so it is susceptible to various protein denaturing 
agents. For example, Spero (1958) showed that the toxin is inactivated 
by alkali; Cartwright and Lauffer (1958) noted that high temperatures 
could decrease toxicity; Boor et al. (1955) discussed toxin inactivation 
and potentiation by the effect 'of salts and colloids; Duff et al. (1956a) 
considered the effects of the buffer used as diluent. Clearly, assay 
procedures must be standardized in that a common and suitable diluent is 
used. This is requisite in order to give workers in this area a common 
basis for discussing results. 
At the present time, suspect material is assayed iji vivo using mice 
or guinea pigs; however, Cartwright and Lauffer (1952) reported the assay 
of toxin using goldfish. This method did not achieve widespread accept­
ance . Fifty per cent endpoints are determined based on per cent survivors 
and are analyzed according to the probit method of either Reed and Muench 
(1938) or Weiss (1948). The report by Schantz et al. (1958) stating that 
bioassay can underestimate true toxicity by sixty per cent stimulated 
even greater interest in the development of an in vitro assay method. 
Early work in this area by Lamanna (1948) showed that both 
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crystalline and amorphous preparations of type A toxin were capable of 
causing hemagglutination of red blood cells of chickens, guinea pigs, 
rabbits, sheep, and man. This report caused considerable interest, not 
only because agglutination of red blood cells could be quantitated, and 
therefore, possibly used as an _in vitro assay method, but also because it 
had always been thought that the toxin was a homogenous toxic protein. 
It was also shown that antitoxin specifically prevented the hemagglutina­
tion reaction. Lamanna and Lowenthal (1951) later showed that the hemag­
glutination caused by type A toxin was due to a component separable from 
the toxin. Since these same workers discovered that type B antitoxin is 
capable of neutralizing the hemagglutinating activity but not the toxicity 
of type A toxin, the possibility of its application as an assay method 
was discarded. Wagman (1954) determined that the agglutinin particles 
are very small nontoxic units which can be removed from the toxin without 
loss of toxicity. The advantages, limitations, and general applications 
of hemagglutination and hemagglutination-inhibition reactions are dis­
cussed by Stavitsky (1954). 
Workers have continued studying the hemagglutination reaction of 
botulinal toxins. This interest stems partially from the possible role 
of the hemagglutinin in affecting results of vivo as well as in vitro 
assays. Recent work with the system by DasGupta and Boroff (1957), 
showed that chromatographic isolation of hemagglutinin-free toxin was 
possible. However, Schantz (1968)* has determined that this 'pure' 
*Schantz, E, J., United States Army Biological Laboratories, Fort 
Detrick, Maryland. The dissociation of hemagglutinin-free type A botu-
linum toxin. Private communication. 1968. 
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— toxin becomes almost completely atoxic within a week. Thus, since 'pure' 
toxin is highly unstable, assays must be performed using toxin which is 
still part of the hemagglutinin-toxin complex elaborated by the organism. 
Other possibilities for in vitro assay of type A toxin have been 
studied. Boroff and Fitzgerald (1958), for example, noted a relation­
ship between toxicity and fluorescence of type A toxin, and determined 
that both of these properties of the toxin decrease with an increase in 
pH. However, Schantz et al. (1960) found that the specific region of 
the toxin molecule responsible for toxicity is not responsible for fluores­
cence. Thus, this system could not be used as the basis of an ^  vitro 
assay. Johnson et al. (1965) studied serological procedures which might 
be applicable to the detection of botulinal toxins in foods. However, 
this method is rather cumbersome and has proved to be of little practical 
importance, 
Recently, Marshall and Quinn (1967) showed that type A toxin is 
capable of inhibiting the enzyme acetylcholinesterase _in vitro, and also 
that the inhibition is detectable spectrophotometrically. Reports con­
cerning the vitro estimation of organic phosphate inhibitors of 
acetylcholinesterase are many and since type A toxin does inhibit acetyl­
cholinesterase, spot tests based on the methods of Cook (1955a, 1955b) 
and Sandi and Wight (1961), for example, may be used to show enzyme in­
hibition qualitatively. However, techniques to quantitate the toxin are 
needed for an assay method. Also, to determine just how the inhibition 
is accomplished, kinetic studies must be done, preferably based on the 
methods given by Dixon and Webb (1964). Characteristics of the enzyme, 
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which were described by Wilson (1961) must be considered, as well as the 
physiological activity of the enzyme as discussed by Fatt and Katz (1951), 
Takeuchi and Takeuchi (1959), Burnstock and Holman (1961), Bell and Burn-
stock (1965), Boter and Ooms (1967), Karlin (1967), and Robinson and 
Bell (1967). 
10 
MATERIALS AND METHODS 
Reagents 
Crystalline type A botulinal toxin was kindly supplied by 
E. J. Schantz, United States Army Biological Laboratories, Fort De-
trick, Maryland. This toxin was composed of both the hemagglutinin and 
toxin components. Purified crystalline antitoxin, types A, B, and E, 
was supplied by the Communicable Disease Center, Atlanta, Georgia. 
Bovine plasma albumin was supplied by Manuel Coria, National Animal 
Disease Laboratories, Ames, Iowa. 
Lactic acid dehydrogenase (type III) was purchased from the Sigma 
Chemical Company, St. Louis, Missouri and its substrate, sodium lactate, 
from Fisher Laboratory Chemical, Fair Lawn, New Jersey. The enzymes, 
acetylcholinesterase (types I and III) and cholinesterase (type IV), as 
well as their substrate, acetylcholine chloride, were also obtained from 
Sigma. The chromogenic substrate of the esterases, indophenyl acetate 
(IPA), was obtained from Mann Research Laboratories, New York, New York. 
Nicotinamide adenine dinucleotide (NAD) was purchased from Calbiochem, 
Los Angeles, California, and Tris buffer, from Aldrich Chemicals, Mil­
waukee, Wisconsin. 
Assay of Type A Botulinal Toxin 
In vivo 
The crystalline toxin was reconstituted and diluted for use in 0.9 
per cent saline. One tenth ml of each dilution was used for 
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intraperitoneal injection of each of ten white Swiss mice, 18-22 g, 
obtained from the Midwest Animal Colonies, Corning, Iowa. Number of 
deaths was recorded over a four day period, and LD^ g values were de­
termined by the method of Weiss (1948) after three replications of the 
assay had been completed. 
In vitro 
Acetylcholinesterase inhibition by type A toxin Preliminary 
studies on this system were based on qualitative methods for detecting 
organic phosphate inhibitors of acetylcholinesterase activity on acetyl­
choline (Cook, 1955a, 1955b). The fact that inhibition of acetyl­
cholinesterase occurs _in vitro through the action of type A botulinum 
toxin was reported earlier by Marshall and Quinn (1967). The spectro-
photometric methods and equipment used by these workers were also used 
in these studies. In order to characterize the type of inhibition in­
volved in this system, a Lineweaver-Burk plot was accomplished using 
1.00 X 10~^ M, 1.25 X 10"\, 1.50 x lO'^ M, 2.50 x 10"^ M, 5.00 x 10"^ M, 
and 7.50 x 10 M concentrations of IPA. The reaction mixture was com­
posed of 10 ^ mg/ml (0.3 LD^ /^ml) type A botulinum toxin, IPA, and 
type III acetylcholinesterase at a final concentration of 0.25 |iM 
units/ml. Eight replications of the data for the plot were made, and 
the individual slopes in each replication were obtained by averaging 
eight values over the entire chart since the velocity did not change in 
the time interval used (60 min), i.e., each subsequent value was identi­
cal, excepting for experimental error, to that of the initial velocity. 
The values obtained for velocity varied less than one per cent and so were 
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averaged to give the greatest level of precision obtainable. 
The gradient of inhibition produced by the toxin was tested using 
-5 2.50 X 10 M IPA, type III acetylcholinesterase, and varying concentra­
tions of botulinum toxin. Each assay was run in quadruplicate and the 
final optical density value was used for extrapolation to zero in order 
to demonstrate the gradient of inhibition which occurs due to the toxin. 
A dose-response curve was constructed using fifteen concentrations of 
toxin to determine the applicability of this inhibition system for assay 
of the toxin in vitro. 
Specificity of inhibition for biologically active toxin To de­
termine the specificity of the inhibition reaction for active type A 
botulinum toxin, type A antitoxin was diluted to titer and added to the 
toxin. This mixture was incubated at 37C for 30 min before addition of 
type III acetylcholinesterase. Inactivation of the toxin (at an initial 
potency of 3 x lO^ LD^ g/ml) was accomplished by three alternate procedures, 
namely (a) by alkali treatment (O.OIN NaOH, pH 12, 3 hr); (b) by boiling 
the toxin for 15 min; and (c) by 3 months' storage in 0.9 per cent NaCl, 
pH 7.2, at 4C under air atmosphere. To be sure that following such 
treatments botulinum toxin was indeed inactive, 10 white Swiss mice, 
18-22 g, were injected with both (a) the equivalent of 3 x 10^ LD 
J\J 
doses of treated toxin and (b) a similar dose of untreated toxin. The 
surviving animals were observed for 7 days. 
Specificity of inhibition for type III acetylcholinesterase As­
says were run, based on the procedures used previously with type III 
acetylcholinesterase, using 0.25 UN units/ml final concentration of 
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acetylcholinesterase (type I) and 0.25 jiM units/ml final concentration 
of cholinesterase (type IV) to test the effect of type A botulinal toxin 
on these systems. 
Lactic acid dehydrogenase (type III), 0.0001 rag/ml final concentra­
tion, was also used in these studies and was assayed using the method of 
Ames, et al. (1963). These assays were run on a two-channe.1 Beckman DB 
recording spectrophotometer after incubating the toxin and enzyme at 
» 
room temperature for 0 min, 10 min, 20 min, and 30 min. Control assays 
were run using (a) sodium lactate, 5 mg/ml and the enzyme to test for 
activity, and (b) sodium lactate, 5 mg/ml, with the appropriate dilution 
of toxin to test for possible changes in optical density in the absence 
of the enzyme. 
- 2  ,  
The dilutions of toxin used in each of these assays were 10 mg/ml 
-9 through 10 mg/ml. Two duplications of each assay were run. 
Assay of type A botulinum toxin using acetylcholinesterase inhibi­
tion To develop the system for in vitro assay of type A toxin, ten 
-10 , 
doses of the toxin were chosen for further study, i.e., 1 x 10 mg/ml 
(0.003 LD^ /^ml), 2 x 10"^ °mg/ml (0.006 LD^ /^ml), 1 x 10"^ mg/ml (0.03 
LD^ g/ml), 1 X 10'®mg/ml (0.3 LD^ g/ml), 2 x 10"^ mg/ml (0.6 LD^ /^ml), 
5 X 10"^ mg/ml (1.5 LD^ /^ml), 1 x 10"^ mg/ml (3 LD^ /^ml), 1 x 10"^ mg/ml 
(30 LD^ /^ml), 2 x 10"^ mg/ml (60 LD^ /^ml), and 1 x 10"^ mg/ml (300 LD^ g/ml). 
Each dose was characterized, using 2.50 x 10"% IPA and 0.25 nM units/ml 
of type III acetylcholinesterase, by the methods given by Marshall and 
Quinn (1967). However, in these experiments, the toxin and enzyme were 
incubated together for 20 min prior to IPA addition and the course of 
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each inhibition curve was charted for 100 min. Each dose was used in 
twenty separate experiments and after the charting was completed, the 
slope of each curve was determined using the value between 40 min and 
60 min on the chart. Statistical analysis of the data was made using 
conventional methods (Finney, 1952, Steel and Torrie, 1960). 
In order to determine the ability of the assay to detect and quanti-
tate toxin in food samples, assays were run, based on normal procedures, 
using hamburger and pea broth as vehicles for toxin. Broths were pre­
pared by boiling 50 g hamburger in 100 ml tap water and 10 g peas in 
50 ml tap water. Both samples were boiled for 5 min. The suspended 
material in each sample was allowed to settle for 8 hr before toxin 
dilutions were added. Final concentrations of toxin used in the two 
food broths were 1 x 10"^ mg/ml, 1 x 10 ^ mg/ml, 2 x 10 ^ mg/ml, and 
1 X 10"^ mg/ml. All assays were run in duplicate. 
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RESULTS AND DISCUSSION 
Assay of Type A Botulinal Toxin 
In vivo 
The botulinal A toxin had a potency of 3 x lO^ m^ouse LD^ /^g. The 
variability, over three replications was very small, indicating that 
maximal precision was obtained in determining the estimate of toxin 
potency. 
In vitro 
Acetylcholinesterase inhibition by type A toxin Spot tests per­
formed in an attempt to show inhibition of type III acetylcholinesterase 
by the toxin indicated that such inhibition was occurring in the system. 
In fact, using this qualitative approach, it was possible to detect as 
little as 10"^ LD^ Q of toxin. This method could be used as a means for 
the detection of toxin in foods or other types of carrier materials; 
however, qualitative techniques, although useful, cannot serve as the 
basis for an assay procedure. Therefore, the same enzyme, type III 
acetylcholinesterase, was used with the chromogenic substrate in the 
development of spectrophotometric analyses. 
There was a definite and reproducible inhibition of type III acetyl­
cholinesterase activity by the botulinal toxin appearing as a difference 
in optical density values in test versus control readings over the time 
interval specified (Table 1). Indeed, the standard slopes of the inhibi­
tion curves, obtained directly, were significantly different. The 
16a 
Table 1. Final optical density values at 625 m|i, obtained at specified 
time intervals by use of indophenyl acetate (IPA), acetyl­
cholinesterase (Ac'ase, type III), types A, B, and E antitoxin, 
and type A botulinum toxin in enzyme inhibition studies 
(Marshall and Quinn, 1967) 
Reaction mixture components 
and concentrations^  OD 
Time Difference 
(min) OD units^  
Ac'ase^  + IPA + 3.3 x 10 ^ mg of toxin .409 48 
Ac'ase + IPA .560 48 .151 
Ac'ase + IPA + 3.3 x 10 mg of toxin 
+ A antitoxin^  
Ac'ase + IPA 
.564 
.560 
48 
48 .004 
Ac'ase + IPA + 3.3 x 10" mg of toxin 
+ A antitoxin® 
Ac'ase + IPA 
.517 
.560 
48 
48 .043 
Ac'ase + IPA + 3.3 x 10"^ mg of toxin 
+ B antitoxin 
Ac 'ase + IPA 
.441 
.560 
48 
48 .119 
F^inal volume, 3.0 ml per cuvette. 
D^ifference in the OD of the cuvette without toxin and the cuvette 
with toxin or with toxin and antitoxin, as specified. 
C^oncentration of Ac'ase was 5.0 units/ml (0.25 jiM unit/ml) unless 
otherwise specified; toxin and enzyme were incubated for 10 min prior to 
IPA addition except where noted. 
T^oxin and antitoxin were incubated for 10 min prior to addition of 
enzyme except where noted. 
T^oxin and Ac'ase were incubated for 30 min at 25C before being 
added to the reaction mixture. 
Table 1. (Continued) 
Reaction mixture components 
and concentrations^  OD 
Time Difference 
(min) OD units^  
Ac'ase + IPA + 3.3 x 10" mg of toxin 
+ E antitoxin 
Ac-ase + IPA 
.426 
.560 
48 
48 .134 
Ac'ase + IPA + 3.3 x 10~^ m^g of toxin 
Ac 'ase + IPA 
.457 
.560 
48 
48 ,103 
Ac'ase (0.5 /ml) + IPA + 3.3 x 10"^ °mg 
of toxin 
Ac'ase (0.5 /ml) + IPA 
.382 120 
.560 120 ,178 
Ac'ase + IPA + 3.3 x 10 mg of 
toxin + A antitoxin 
Ac 'ase + IPA 
.551 
.560 
48 
48 .009 
Ac 'ase + IPA + 3.3 x 10 mg of 
toxin + B antitoxin 
Ac 'ase + IPA 
.460 
.560 
48 
48 ,100 
Ac'ase + IPA + 3.3 x 10 mg of toxin 
+ E antitoxin 
Ac'ase + IPA 
.458 
.560 
48 
48 ,102 
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inhibition by the toxin was presumably due to a binding with, or a masking 
of, either or both the active combining site and the specificity site on 
the enzyme molecule. The incubation of homologous antitoxin with toxin 
before enzyme addition completely reversed this action and prevented all 
enzyme inhibition at both toxin concentrations used. Absolute specificity 
of the enzyme inhibition by the toxin was revealed through the ineffec­
tiveness in blocking toxin activity by heterologous antitoxins (types B 
and E) at either toxin concentration and through the partial release of 
inhibition by addition of homologous antitoxin after enzyme addition. In 
fact, the serological cross-reaction observed by Lamanna and Lowenthal 
(1951) between type A toxin and type B antitoxin obviously did not occur 
in this system. Although type III acetylcholinesterase inhibition is 
reproducible and constant for given toxin, enzyme, and substrate con­
centrations, enzyme inhibition is never complete. 
It was found that the difference in optical density (amount of inhibi­
tion of the enzyme by the toxin) could be increased by keeping the enzyme 
and substrate concentrations constant while increasing the toxin con­
centration, or by decreasing the enzyme concentration and increasing the 
incubation time. Also, when toxin A and antitoxin A were incubated for 
10 min prior to the addition of enzyme and when this mixture was then 
incubated for 10 min before IPA addition, a total reversal of enzyme 
inhibition was obtained. However, when toxin A and enzyme were incubated 
for 30 min prior to the addition of antitoxin A and when this mixture 
was then incubated for an additional 10 min before addition of IPA, an 
incomplete enzyme inhibition was obtained; that is, about half the 
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optical density difference was observed relative to that in the toxin-
enzyme system incubated for only 10 min. From these data, it was specu­
lated that there may be an action of type III acetylcholinesterase on 
the toxin such that release of small toxic, but not antigenic, fragments 
occurs. According to this speculation, there would be partial inhibition 
of enzyme activity by toxin fragments not binding to antitoxin and whose 
concentration would be related to the time of incubation or of exposure 
of toxin to the enzyme molecule. The data in Table 1 indicate that some 
system may be causing a potentiation of toxicity such that the amount of 
antitoxin required for neutralization is no longer sufficient to prevent 
enzyme inhibition. The preceding discussion was taken from Marshall and 
Quinn (1967). 
As mentioned previously, inhibition of type III acetylcholinesterase 
activity by type A botulinum toxin was only partially reversed by addi­
tion to the system of type A antitoxin which had been diluted to titer, 
whereas the addition of heterologous antitoxins did not produce even a 
partial reversal of the toxin-induced inhibition. Therefore, the enzyme 
inhibition by the toxin is due only to the toxic portion of the toxin 
molecule and not to enzyme involvement with hemagglutinin (Lamanna, 1948, 
Lamanna and Lowenthal, 1951). 
The inhibition response pattern noted (Table 1, Figure 1) would be 
typical of the 'mixed' type of inhibition of the enzyme (Dixon and Webb, 
1964), as only a proportion of the toxin activity is susceptible to 
neutralization by specific antitoxin after toxin-enzyme interaction. 
This observation was validated by the Lineweaver-Burk plot (Figure 2) 
Figure 1. Gradient of inhibition of acetylcholinesterase activity on 
indophenyl acetate by type A botulinum toxin of the following 
concentrations: O—O control, (no toxin) A 1 x 10"^ mg 
toxin, (3 X 10 LD^ g/ml); O • 2 x 10~^ mg toxin, 
(6 X 10 LD q^/hiI) ; Q-—O 1 x 10"^ mg toxin, (3 x lO'^ LD^ g/ml) ; 
A A 2 X 10"^ mg toxin, (6 x lO^ L^D^ g/ml) ;Q——g 1 x 10"^ m^g 
toxin, (3 X lO'^ LD^ g/ml) ; © ©2 x 10~^ ®mg toxin, 
(6 X lO'^ LD^ g/ml) 
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Figure 2. Lineweaver-Burk plot of the interaction between type III 
acetylcholinesterase (0.25 jiM units), indophenyl acetate 
(2.5 X 10"^  M ) , and type A botulinum toxin (0.3 LD^ Q/hiI) 
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Table 2. Data for the Lineweaver-Burk plot of the action of acetyl­
cholinesterase (0.25 [jM units/ml) with and without type A 
botulinum toxin (10"^mg/ml; 0.3LD^Q/0.1 ml) on indophenyl 
acetate (2.5 x lO'^M ) at 22C using light of 625 
{s} (IPA)^ i/(s7 1/V^ 
(with toxin) 
1/V^ 
(without toxin) 
1.50 X 10"\ 0.67 1.20 1.00 
1.25 X lO'^M 0.80 1.32 1.07 
1.00 X 10"^M 1.00 1.45 1.15 
7.50 X 10"^M 1.33 1.65 1.35 
5.00 X lO'^M 2,00 2.15 1.60 
2.50 X 10"^M 4.00 3.40 2.60 
^olar concentration of IPA. 
^Reciprocal of molar concentration of IPA coded by deleting lO^M 
from each concentration. 
^Reciprocal of slope of inhibition curve at designated IPA con­
centrations (averaged values of 8 replications). 
^Reciprocal of slope of IPA and enzyme curves at designated IPA 
concentrations (averaged values of 8 replications). 
which was based on the values in Table 2. The partial inhibition of 
acetylcholinesterase by botulinum toxin in the presence of antitoxin 
specific for the toxin serotype, is better explained by the reversible 
nature of a part of the enzyme inhibition which is characteristic of the 
mixed type of inhibition, than by the fragmentation of toxin to give 
nonantigenic but toxic fragments as was speculated earlier (Marshall 
and Quinn, 1967). Complete inhibition of the enzyme activity by 
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botulinum toxin would not be possible in this system regardless of the 
concentration of toxin used, and complete enzyme inhibition was never 
obtained experimentally. A complete lack of inhibition of the enzyme 
is obtained only when the toxin and homologous antitoxin are incubated 
before enzyme addition. 
As was seen in Figure 1, there is a gradual decrease in enzyme 
inhibition produced by decreasing the concentration of botulinum toxin, 
The fact that this gradient occurs consistently and that the slopes and 
the final inhibition values for any given concentration of toxin are 
highly reproducible indicated the value of this method for in vitro 
assay of type A botulinum toxin. Indeed, a dose-response curve was 
constructed using fifteen concentrations of the toxin. Table 3 gives 
the actual doses in mg/ml and the LD^^doses/ml which are equivalent to 
the transformed abscissa values. The dose-response curve is given in 
Figure 3. In Table 4 the slope values at each dose level are found. 
Since monotonocity is a strict requirement for the dose-response curve 
in a valid assay situation, the linear portion of the curve at the lower 
dose levels only (10 ^^mg/ml through 10 ^ mg/ml) was used for development 
of the assay. 
Specificity of inhibition for biologically active toxin Those 
mice injected with inactivated toxin preparations showed, over the 
course of the observation period, a complete lack of those typical 
symptoms which occur after the injection of active toxin, while control 
animals, injected with siaiilar size doses of untreated toxin, died 
within an hour. It was shown that those mice injected with the storage 
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Table 3. Concentration of type A botulinum toxin in actual dose, 
transformed dose, and LD^g dose used in the construction 
of dose-response curves 
Actual dose mg/ml = Transformed dose^ LD50 dose/ml 
1 X 0 3 X 10"^ 
2 X 10-'° 0.301 6 X 10'^ 
1 X 10"^ 1 3 X 10"^ 
1 X 10-8 2 3 X 10"^ 
2 X 10-8 2.301 6 X 10-^ 
5 X 
00 1 o
 
t —1 
2.699 1.5 
1 X 10"^ 3 3 
1 X 10"^ 4 30 
2 X 10"^ 4.301 60 
1 X 10"^ 5 3 X 10^ 
1 X 10""^ 6 3 X 10^ 
1 X 10"^ 7 3 X 10^ 
1 X lo"^ 8 3 X 10^ 
1 X 10"^ 9 3 X 10^ 
1 10 3 X 10^ 
(log^^ dose mg/ml) + 10. 
Figure 3. Dose-response curve constructed using slope determinations after 
assaying fifteen concentrations of type A botulinal toxin using 
acetylcholinesterase inhibition 
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Table 4. Slope values from in vitro assays of the inhibition of acetylcholinesterase 
using fifteen dose levels of type A botulinum toxin 
Toxin log 
dose + 10 Slope 
0 .78,.72,.79, .71,.70,.80,.70,.71,.77,.72,.71,.76,.75,.83,.70,.81,.69,.70,.68,.78 
0.301 .68,.74,.70,.67,.73,.70,.70,.62,.65,.71,.75,.71,.68,.77,.74,.70,.67,.74,.71,.70 
1.0 .64, .68, .66, .72, .62,.68,.62,.63,.64,.70,.61,.64,.68,.62,.70,.60,.63,.64,.61,.66 
2.0 .56,. 56,. 60,. 58,. 56,. 61,.48,. 58,. 59,. 48,. 46,. 48,. 58,. 58,. 55,.49,. 58,. 59,. 53,-.48 
2.301 .60,.61,.51,.52,.60,.50,.50,.46,.52,.60,.52,.52,.48,.53,.50,.52,.50,.53,.52,.50 
2.699 .51,.54,.50,.48,.52,.56,.48,.46,.48,.49,.52,.46,.48,.47,.46,.51,.48,.50,.40,.51 
3 .46,.41,.53,.46,.40,.53,.48,.45,.43,.43,.54,.52,.40,.44,.52,.55,.43,.46,.42,.43 
4 .38,.36,.36,.44,.42,.34,.36,.36,.39,.40,.44 .36,.37,.33,.38,.41,.37,.38,.44,.36 
4.301 ,34,,36,.25,.35,.33,.32,.36,.32,.38,.35,.38,.28,.36,.38,.34,.35,.36,.30,.28,.38 
5 .32,.26,.28,.22,.30,.24,.30,.24,.33,.26,.20,.32,.27,.25,.29,.30,.26,.28,.30,.27 
6 .35,,29,.36,.38,.37,.33,.35,.32,.37,.29,.35,.39,.33,.35,.36,.31,.30,.37,.33,.29 
7 .46,.50,.41,.43,.49,.52,.56 .52,.50,.46,.49,.48,.50,.43,.49,.53,.56,.52,.50,.49 
8 .65,.52,.58,.63,.61,.57,.58,.53,.59,.58,.59,.60,.58,.63,.54,.56,.55,.51,.58,.56 
9 .60,.68,.73,.70,.65,.69,.65,.61,.72,.70,.68,.69,.61,.63,.64,.62,.63,.67,.68,,70 
10 .68,.70,.69,.68,.64,.71,.60,.68,.65,.68,.60,.60,.68,.67,.66,.71,.72,.68,.60,.61 
29 
inactivated toxin preparation were able to withstand injection of 
30 doses of active toxin after a two-week rest period, which indi­
cated that this preparation was acting as a toxoid. Injection of heat-
inactivated and alkali-inactivated toxin preparations did not protect . 
mice injected with 30 LD^Q doses of active toxin after a two-week rest 
period. Since the dosage of toxin injected was so great, it can be said 
that a complete loss of the biological activity of the toxin must have 
been produced by the various inactivation techniques. In vitro toxin 
assays were made using toxin more dilute than that used in the _in vivo 
test so that a complete lack of biological potency of the toxin could 
be assumed if mice were able to survive the test. 
Using toxin inactivated by the various methods, employing normal 
procedures for the assay, and comparing the slope and final optical 
density values after a specified time interval (100 min), it was seen 
that the slopes of the resultant plots was exactly that of the IPA plus 
enzyme controls. In the positive controls, untreated toxin inhibited 
the enzyme in the expected manner. This finding has interesting physio­
logical implications since it indicates that botulinum toxin must be in 
a biologically active form in order to inhibit the action of the enzyme 
in vitro ; in other words, toxoid preparations apparently have no effect 
on the enzyme. Studies were not done, however, to test for in vivo 
enzyme inhibition. A recent study by Malaney and Davis (1967) has 
shown that acetylcholinesterase inhibition due to micropollutants in 
drinking water produces symptoms in humans referrable to the nervous 
system. This finding gives some credance to the idea that some of the 
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symptoms seen in botulism intoxication could be due to the inhibition 
of acetylcholinesterase. However, in vivo inhibition of this enzyme by 
the toxin has not been demonstrated experimentally. 
Specificity of inhibition for type III acetylcholinesterase Assays 
which were run using type I acetylcholinesterase and type IV cholines-
terase indicated that the typical toxin-induced enzyme inhibition •vrtiich 
is seen with type III acetylcholinesterase does not occur as such in 
these systems. A slight amount of inhibition was noted using type I 
acetylcholinesterase; however, at the enzyme and substrate concentra­
tions used, the slope of the inhibition curves was less than 0.1 unit 
below the control curves regardless of toxin concentration. The IPA 
plus enzyme controls were typical of those seen with type III acetyl­
cholinesterase. The nonspecific type IV cholinesterase used in these 
studies was not inhibited by the toxin at the enzyme-substrate-toxin 
concentrations used. It can be concluded from these results that 
neither of these systems could greatly influence the results of iji vitro 
assays using type III acetylcholinesterase with suspect material con­
taining these other esterases. The studies performed using lactic acid 
dehydrogenase showed a complete lack of enzyme inhibition by the toxin, 
and therefore, the presence of this enzyme in suspect material would not 
affect jji vitro assay of the toxin using the acetylcholinesterase-IPA 
system. 
Unfortunately, it cannot be concluded that the assay system de­
veloped from the inhibition of type III acetylcholinesterase on the 
chromogenic substrate will be impervious to either potentiation or 
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negation of typical inhibition curves. It is quite possible that there 
exists an enzyme or a material of some nature in suspect material which 
could affect the results of the inhibition of enzyme activity by the 
toxin. However, it is not possible to test this likelihood without 
extensive practical application of the assay itself. 
Assay of type A botulinum toxin using acetylcholinesterase inhibi­
tion The linear curve which was established by the use of the toxin-
induced enzyme inhibition is given in Figure 4. Only those concentra­
tions of toxin between 10 ^^mg/ml and 10 ^ mg/ml can be quantitated using 
this method. As can be seen in Figure 3, concentration effects and un­
explained interferences in the system cause an increase in slope (de­
creased inhibition of enzyme) above toxin concentrations of 10 ^ mg/ml. 
Thus, the assay must be restricted to dose levels below this amount. A 
possible explanation for the concentration effects may be the polymeriza­
tion or aggregation of the toxin molecules at concentrations above 
10 ^mg/ml. That this phenomenon does occur with proteins has been dis­
cussed, for example, by Kuff et al. (1955) and by Thomson and Moss (1956). 
It is a well-accepted fact that proteins and globulins will aggregate or 
polymerize if these materials are present in solution in high concentra­
tion. If this- phenomenon occurs with concentrations of toxin above 
10 ^ mg/ml, the decreased inhibition could be due to a masking of the 
site(s) on the toxin molecule which interacts with and inhibits type III 
acetylcholinesterase activity. In this way, then, the change of slope 
seen in Figure 3 could be explained. However, it must be mentioned that 
the range of effectiveness of this assay is in the area of interest for 
Figure 4. Dose-response curve of botulinum A toxin using acetylcholinesterase 
(type III) inhibition ' 
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quantitation studies. Dilutions of suspect material must also be made 
using vivo assay techniques in order that an endpoint may be reached. 
The analysis of variance of six of the doses used for the assay is 
given in Table'5. This analysis was performed using only the six 
equally-spaced doses from 10 ^^mg/ml through 10 ^mg/ml in order to 
simplify the statistical methods. It is obvious that there is a sig­
nificant difference in the response to the treatments and also that the 
bulk of the variation among the contrasts can be explained by linear re­
gression. Since the quadratic, cubic, quartic, and quintic comparisons 
are not significant, a straight line may be drawn through the points to 
characterize the enzyme inhibition; the slope of the regression line was 
calculated to be -0.91. 
Table 5. Analysis of variance on the slope determinations at six 
equally-spaced doses 
Source Df SS MS pa 
Treatments 5 2.9506 0.5901 295.05 
linear (1) 2.9459 2.9459 1472.95 
quadratic (1) 0.0000005 0.0000005 0.00025 
cubic (1) 0.0021 • 0.0021 1.05 
quartic 0.0024 0.0024 1.2 
quintic (1) 0.0002 0.0002 0.10 
Within treatments 114 0.1971 0.002 
^Tabular ^ F 
114 
^^Significant 
= 2.29 at 0.05 Tabular ,^,F = 
114 
3.92 at 0.05. 
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Assays made on hamburger and pea broth using the final assay pro­
cedure showed that salts and other food materials from these samples did 
not interfere with the typical inhibition response (Table 6). The assay 
procedure enabled quantitation of toxin in these two food samples, and 
will provide a means for detecting and quantitating type A botulinum-
toxin. 
Table 6. Assay for type A botulinal toxin using hamburger and pea broths 
as vehicles for toxin 
Toxin con- _ , -, ^ 
. . . Hamburger broth Pea broth 
centratxon o c c o 
mg/ml 1x10'^ 1x10-7 2xl0"°- IxlO'^ 1x10"^ IxlO'^ 2x10"° 1x10"^ 
Slope .54 .48 .34 .27 .55 ;48 .35 .28 
Values .56 .46 .34 .30 .57 .44 .32 .26 
35a 
summary 
In vitro assay of the A serotype of botulinum toxin using a system 
of enzyme inhibition has been discussed. The assay procedure, given 
below, has enabled quantitation of toxin. 
1) Set recording spectrophotometer to read 625 mu wavelength 
transmission and equilibrate the sample holder temperature 
to 22C 
2) Incubate 0.1 ml toxin and 0.1 ml enzyme (25 uM units/ml) 
together for 20 min 
3) Add 0.1 ml IPA (2.5 x 10"'Sl) to the toxin-enzyme mixture and 
dilute with Clark-Lubs buffer, pH 8.0, to 10 ml 
4) Set up controls using IPA + buffer, as well as IPA + enzyme + 
buffer (the final volume in all four flasks should be 10 ml) 
5) Transfer 3 ml of. each reaction mixture to a spectrophotometer 
cuvette with a 1 cm light path, and begin to chart the reaction 
6) Allow 60 min to elapse before the reaction is stopped 
7) Determine the slope of the curve (for the system toxin-enzyme-
IPA) as well as that of the IPA + enzyme control, by measuring 
the slope value established during the 50-60 min interval on 
the absorbance trace given on the recorder chart 
8) Determine the toxin concentration in the unknown by comparing 
this slope value with those given in Table 4 
Although this in vitro assay method has been shown to be effective 
when using purified reagents, its worth in a practical sense has yet to 
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be evaluated. Many analytical problems may arise. For example, how can 
one be sure that enzyme inhibition is due to toxin alone and not to 
some other material present in the toxin-containing sample? Can one be 
sure that a latk of enzyme inhibition is due to the absence of the 
toxin, or is it perhaps due to an interference of some nature with 
toxin activity? Will this assay give the same results when either 
'pure' or crude toxin is used or when purified Ç. botulinum hemagglutinin 
is used? The potential areas of study originating with the development 
of this assay are many. 
More work is needed to clarify the kinetics of the decrease in 
acetylcholinesterase inhibition by the toxin above a concentration of 
10 ^mg/ml. The fact that decreased inhibition occurs is obvious, but 
the reason for this decrease is not. What exact effect does the toxin 
have on the enzyme? There is much work left to be done on this system 
especially considering the practical applications. As such, however, 
the system will enable a precise and rapid assay method at least for 
purified toxin preparations in laboratory situations. 
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APPENDIX 
Table 7. Mouse assay of type A botulinum toxin using the method of Weiss (1948) 
Dose toxin Rep. I Rep. II Rep. Ill 
mg/ml logj^Q (mg/ml) Survivors Probit Survivors Probit Survivors Probit 
No. tested No. tested No. tested 
3 x 10"^ -0.52 0/10 3.22 0/10 3.22 0/10 3.22 
3 x lo"^ -1.52 0/10 3.22 0/10 3.22 0/10 3.22 
3 x 10"^ -2.52 0/10 3.22 0/10 3.22 0/10 3.22 
3 x 10"'^ -3.52 0/10 3.22 0/10 3.22 0/10 3.22 
3 x 10"^ 
-4.52 0/10 3.22 0/10 3.22 0/10 3.22 
3 x 10"^ -5.52 2/10 4.16 3/10 4.48 2/10 4.16 
3 x 10"^ -6.52 5/10 5.00 5/10 5.00 5/10 5.00 
3 x 10-8 
-7.52 10/10 7.14 10/10 7.14 10/10 7.14 
3 x 10"^ -8.52 10/10 7.14 10/10 7.14 10/10 7.14 
0 - - — - 10/10 7.14 10/10 7.14 10/10 7.14 
M = log^^ LD^^/mg = -6.52 Relative potency estimators: 
SE log^Q LD^^/mg = 0.174 R^ = antilog = 2 x 10^ LD^^/mg 
>L = -6.52 + (-0.174) = -6.694 R = antilog M = 3 x 10^ LD /mg 
ij 50 
Mg = -6.52 + (+0.174) = -6.346 = antilog M^ = 4.6 x 10^ LD^^/mg 
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Table 8. Slope values from assays made using type I acetylcholinesterase 
(ACE-I), type IV cholinesterase (CE-IV), and type III acetyl­
cholinesterase (ACE-III) with IPA to determine the effect of 
type A botulinum toxin on enzyme activity (slope values de­
termined using the interval from 40 min to 50 min on the 
Gilford chart) 
Toxin mg/ral ACE-I CE-IV ACE-III 
-2 
1 x 10 0.85 0.87 0.83 0.89 0.59 0.60 
1 x 10"^ 0.86 0.86 0.87 0.85 0.50 0.49 
1 x 10*4 0.76 0.79 0.85 0.82 0.34 0.37 
1 x 10"^ 0.73 0.82 0.85 0.79 0.27 0.22 
1 x lO'G 0.80 0.76 0.86 0.81 0.38 0.38 
1 x lO'^ 0.80 0.73 0.81 0,85 0.43 0.46 
1 x 10"G 0.75 0.77 0.80 0.79 0.55 0.54 
1 x 10"^ 0.72 0.80 0.82 0.83 0.65 0.62 
0 0.86 0.81 0.84 0.85 0.86 0.85 
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Table 9. Effect of type A botulinum toxin on the activity of lactic 
acid dehydrogenase after incubating the enzyme and toxin for 
varying.time intervals 
Optical density 
Toxin mg/ml 0 min 10 min 20 min 30 min 
1 X lO"^ 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 
1 x 10"^ «L * /  JL * /  J«a/ im » t  JL«/ Ja*# /  
1 x 10*4 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 
1 x 10"^ 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 
1 X lO"^ 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 
1 x 10"7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 
1 X 10 "G 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 
-9 
1 x 10 
control^ 0 0 0 0 0 0 0 0  
b 
control 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 
a 
Assays run without enzyme. 
^Assays run without toxin. 
